

SUMMARY

This summary aims to give you an overview of the information contained in this document. As this is a summary, it does not contain all the information that may be important to you. You should read the entire document carefully before you decide to [REDACTED] in the [REDACTED]. In particular, we are a biotechnology company seeking a [REDACTED] on the Main Board of the Stock Exchange under Chapter 18A of the Listing Rules on the basis that we are unable to meet the requirements under Rule 8.05(1), (2) or (3) of the Listing Rules. Moreover, there are risks associated with any [REDACTED]. Some of the particular risks in [REDACTED] in the [REDACTED] are set out in “Risk Factors.” Our Core Product is the product for the purpose of satisfying the eligibility requirements under Chapter 18A of the Listing Rules and Chapter 2.3 of the Guide. Our Core Product’s expansion of application is in the early stage of clinical development. We may continue to incur substantial costs and expenses in relation to the research and development of our Core Product, and our Core Product may not be successfully marketed.











OVERVIEW

Founded in 2016, we are a biotechnology company focused on and pioneering in the development and commercialization of molecular diagnostic instruments and biochips. As of the Latest Practicable Date, our product offerings span one microarray analyzer, two EL-NGS gene sequencers, as well as various compatible test kits, all of which are in-house developed. Our Core Product, AxiLona EL-100, is one of the few molecular diagnostic products in China capable of performing electrochemistry-based, multi-target, rapid, low-cost, and integrated detection of biomolecules. AxiLona EL-100 currently has nucleic acid detection function, which provides qualitative analysis of current signals from nucleic acid microarray chips, and is intended to expand to include both nucleic acid and protein detection functions.

WE MAY NOT BE ABLE TO ULTIMATELY UPGRADE AND MARKET OUR CORE PRODUCT SUCCESSFULLY.

SUMMARY

The following chart illustrates our pipeline and summarizes the development status of our selected products and product candidates, all of which are in-house developed, as of the Latest Practicable Date:

Product	Main Application	Market/Regulatory Authority	Category	Development Stage				Expected/Actual time for Completion of the Current Stage	Expected/ Actual Clinical Trial Start Time	Expected/ Actual Commercialization Approval Time
				Pre-clinical		Clinical Trial ⁽²⁾	Approval			
				Design	Design Verification					
Devices										
Microarray Analyzer AxiLona EL-100 	Nucleic Acid Detection	EU/EU — German Institute for Medical Documentation and Information	A					Q3 2023	/	Q3 2023
		China/Jiangsu MPA ⁽⁴⁾	II					Q2 2025	Q3 2024	Q2 2025
	Nucleic Acid Detection & Protein Detection ⁽⁵⁾	U.S./FDA	II					Q1 2026	Q3 2026	Q4 2027
		China/Jiangsu MPA ⁽⁴⁾	II					Q1 2026	Q4 2026	Q4 2027
EL-NGS Gene Sequencer AxiLona AXP-100 	Gene Sequencing	U.S./FDA	II					Q1 2026	Q4 2026	Q4 2028
		China/NMPA	III					Q4 2025	Q3 2026	Q2 2028
	Gene Sequencing	U.S./FDA	III					Q2 2025	Q4 2026	Q4 2028
		China/NMPA	III					Q3 2026	Q2 2027	Q2 2029
EL-NGS Gene Sequencer AxiLona AXP-1000	Gene Sequencing	U.S./FDA	III					Q3 2026	Q2 2028	Q4 2030
Test Kits										
Test Kit for X-linked Monogenic Disorder ⁽⁶⁾	Genetic Disease Detection — Fragile X syndrome	China/NMPA	III					Q3 2026	Q4 2026	Q2 2029
		China/NMPA	III					Q2 2026	Q4 2026	Q2 2029
Test Kit for Pathogenic Microorganism ⁽⁶⁾	Respiratory Multiplex testing	China/NMPA	III					Q3 2026	Q4 2026	Q4 2028
		China/NMPA	III					Q3 2026	Q4 2026	Q4 2028
 Core Product	☆ Key Product									
Abbreviations: Q1 means the first quarter; Q2 means the second quarter; Q3 means the third quarter; Q4 means the fourth quarter										

 Core Product

 Key Product

Abbreviations: Q1 means the first quarter; Q2 means the second quarter; Q3 means the third quarter; Q4 means the fourth quarter

Notes:

- (1) For the FDA registration in the U.S., type testing refers to safety and performance testing.
- (2) In the EU, Nucleic Acid Detection is regulated under the In Vitro Diagnostic Regulation (IVDR). Under the IVDR, Nucleic Acid Detection devices classified as Class A are exempt from the requirement for clinical trials.
- (3) Although AxiLona EL-100 for nucleic acid detection and AxiLona EL-100 for both nucleic acid and protein detection differ in detection targets, reagent kits and software modules, they share the same hardware configuration and will be regulated as one product by Jiangsu MPA.
- (4) According to the Administrative Measures for the Registration and Filing of Medical Devices (《醫療器械註冊與備案管理辦法》), as a Class II medical device, AxiLona EL-100 is regulated by the Jiangsu MPA.
- (5) Designed for use in conjunction with AxiLona AXP-100.
- (6) Designed for use in conjunction with AxiLona EL-100.

SUMMARY

OUR STRATEGIC FOCUS AND MARKET OPPORTUNITIES

Our immediate strategic focus is on the commercialization and further application development of our molecular diagnostics products based on our proprietary electrochemical biochip technology. In parallel, as part of our long-term strategy, we will continue to develop our EL-NGS platform with long-read sequencing capabilities. This strategy is driven by the market demands for technologies with faster speed, higher accuracy, and greater accessibility. For details of our journey and business evolution since our inception, see “Business — Our Journey and Strategic Evolution.”

Molecular Diagnostics Products

The market potential for molecular diagnostic products is significant, driven by demand for multiplex, rapid, cost-effective, and integrated detection solutions. According to CIC, the global non-sequencing molecular testing market reached US\$9.8 billion in 2024 and is projected to grow to US\$22.5 billion in 2033, representing a CAGR of 9.7%. Traditional PCR products are generally limited to detecting a small number of targets simultaneously and require multiple processing steps and specialized infrastructure, while NGS technologies, though comprehensive, are often cost-prohibitive and time-consuming. These unmet needs point to the market opportunity for innovative products featuring multiplex detection, lower costs and accelerated testing cycles.

Therefore, we have developed AxiLona EL-100, a molecular diagnostic product based on electrochemical biochip technology, which is one of the few in China capable of performing electrochemistry-based, multi-target, rapid, low-cost, and integrated detection of biomolecules. We have completed the clinical trial for AxiLona EL-100 in March 2025 and have received its registration approval from Jiangsu MPA in April 2025. According to CIC, the global electrochemical multiplex PCR-microarray testing market is projected to grow from US\$397.6 million in 2024 to US\$1,027.8 million in 2033 at a CAGR of 11.1%, with China's market projected to grow from US\$2.2 million to US\$56.4 million at a CAGR of 43.6%. The U.S. and EU markets are projected to reach US\$292.6 million and US\$448.5 million by 2033, respectively, from US\$105.5 million and US\$220.9 million in 2024, respectively. In 2024, the electrochemical multiplex PCR-microarray testing market accounts for approximately 4.1% of the overall non-sequencing molecular testing markets globally, 0.1% in China, 6.7% in the U.S., and 3.8% in the EU.

EL-NGS Platform

Gene sequencing has diverse applications across clinical diagnostics, scientific research, drug development and other fields, representing a market with tremendous long-term growth potential. According to CIC, the global market size of high-throughput gene sequencing reached US\$7.1 billion in 2024, and is expected to achieve US\$21.9 billion in 2033, representing a CAGR of 13.2%. However, mainstream NGS products fall short in meeting the demand for long-read sequencing with high accuracy and low cost, leaving significant unmet needs. We are developing AxiLona AXP-100, which, according to CIC, is the world's first EL-NGS gene sequencer, integrating semiconductor biochips with technologies across biochemistry, integrated circuits, microfluidics, AI, and bioinformatics to deliver long-read, high-accuracy, low-cost, and fast sequencing. According to CIC, the global EL-NGS testing market is estimated to increase from US\$1.4 million in 2024 to US\$501.0 million in 2033 at a CAGR of 91.8%. China's EL-NGS testing market is estimated to increase from US\$1.4 million in 2024 to US\$243.9 million in 2033 at a CAGR of 77.0%. The U.S. and EU EL-NGS testing markets are estimated to increase from nil in 2024 to US\$130.1 million and US\$95.8 million in 2033, respectively. In 2024, the EL-NGS testing market accounts for approximately 0.0% of the overall high-throughput gene sequencing market globally, 0.1% in China, and nil in the U.S. and the EU.

SUMMARY

Expanding Offerings Based on Foundational Technology

Building upon our foundational technologies, we also provide customized small molecule synthesis and high-throughput protein mutagenesis services, and are advancing development of multi-omics detection solutions for multiplex protein marker detection and protein sequencing. In addition, we have developed the AxiLona Library Preparation Robotic System for automated library preparation through a collaborative partnership with a specialized liquid handling module manufacturer.

OUR PRODUCT AND SERVICE PORTFOLIO

Instruments

AxiLona EL-100, our Core Product

AxiLona EL-100 is a molecular diagnostic product based on electrochemical biochip technology. It delivers improved performance over conventional PCR systems, featuring a number of advantages, including multiplex target detection, high sensitivity, high specificity, rapid testing cycle, as well as smooth and safe user experience:

- *Multiplex detection.* AxiLona EL-100 can conduct target detection through 54 addressable electrodes, enabling simultaneous analysis up to 54 targets in a single test run, as validated through engineering and pre-clinical studies. Each target typically represents a characteristic nucleic acid sequence associated with a specific bacterium, virus, or gene of interest.
- *High sensitivity.* It can accurately detect positive samples across varying concentration levels, with a detection limit as low as 100 copies/mL. Our pre-clinical studies demonstrated that it accurately distinguished between positive and negative results across weak-positive, medium-positive, and strong-positive samples, achieving a 100% detection rate for all 85 positive samples.
- *High specificity.* It is capable of accurately differentiating target pathogens from non-target pathogens and minimizing false-positive results. In our preclinical studies, the system analyzed 397 negative samples, with only 2 false-positive reports, yielding a specificity of 99.5% (395/397).
- *Rapid testing cycle.* It also offers a relatively short turnaround time, completing the entire workflow including both automated and manual steps in under two hours, which is considerably faster than many conventional molecular diagnostic methods such as the commonly used multiplex PCR or multiplex PCR microarray platforms, according to CIC.
- *Smooth and safe user experience.* In terms of convenience, evaluation forms from clinical trials indicate that the system features efficient installation and setup, straightforward power-on/off procedures, simple sample loading and testing workflows, an intuitive user interface, easy cleaning and disinfection, and accurate operational status indicators, achieving an average score of 98 out of 100 across multiple evaluations. Furthermore, the device demonstrates favorable safety and stability profile, with no safety issue such as electrical leakage or physical damage, no malfunctions during operation, consistent long-term performance, accurate chip recognition, real-time status display, and automated report storage.

SUMMARY

These features make it well-suited for scientific research supported by research-use-only (RUO) test kits, and for clinical applications supported by test kits developing with regulatory approval or through other pathways, distinguishing it from competing molecular diagnostic products.



Appearance of AxiLona EL-100

AxiLona EL-100 was admitted into the Special Registration Procedures for Innovative Class II Medical Devices (commonly known as Green Path) by the Jiangsu MPA in June 2024. We completed its clinical trial in March 2025, and have received the Class II medical device registration certificate for AxiLona EL-100 from Jiangsu MPA in April 2025. This registration approves our microarray analyzer for the qualitative analysis of signals generated by nucleic acid microarray chips in support of nucleic acid-based medical testing applications, and is not intended for absolute quantification of nucleic acid samples. These microarray chips are components of test kits, and AxiLona EL-100 must be used in conjunction with compatible test kits for any clinical or research use only applications. We also received the CE marking for AxiLona EL-100 in July 2023. We plan to develop an upgraded version to cover both nucleic acid detection and protein detection.

In our completed clinical trial, our AxiLona EL-100 has demonstrated excellent detection consistency with the control system (a commercially available real-time fluorescence quantitative PCR instrument and respiratory pathogen nucleic acid detection kit). Though our AxiLona EL-100 and the control system operate under different technical principles, this clinical trial demonstrates that the consistency rate for the positive samples between our AxiLona EL-100 as the test system and the control system was 100.00%, the consistency rate for the negative samples between our AxiLona EL-100 as the test system and the control system was 100.00%, and the overall consistency rate was 100.00%. The Kappa value was 1.0000 (>0.75), indicating excellent detection consistency between the test system and the control system.

As to functionality, in this clinical trial, each positive and negative quality control sample yielded qualified results, with no instances of quality control failure. Also, during operation, the device correctly identified microarray chips, displayed working status, reported and stored detection results, and functioned normally, demonstrating high stability. The microarray analyzer maintained continuous operation without abnormal operations. As to convenience of use, the average user rating is 98 (out of 100). Furthermore, no safety-related events occurred. For further details, see “Business — Our Product and Service Portfolio — AxiLona EL-100 — Our Core Product.”

Among the existing non-sequencing molecular testing products utilizing multiplex PCR-microarray technologies, a majority of them are based on fluorescence microarray detection and few opine on electrochemical microarray detection which offers higher sensitivity and specificity, greater multiplexing capacity, lower costs, simpler and more compact instrumentation, and a streamlined workflow compared to fluorescence-based systems. As of December 31, 2025, an aggregate of 80 multiplex PCR-microarray testing instruments developed by 58 companies had been approved by the NMPA or its local counterparts, of which only two were electrochemical platforms, including our Core Product

SUMMARY

AxiLona EL-100. In 2024, the top five players in China’s non-sequencing molecular testing market collectively held over 50% of the market share by revenue, with the single largest player accounting for 13.2%. In contrast, the electrochemical multiplex PCR-microarray testing segment was highly concentrated, with the only two approved instruments capturing the entire market share in China for the same year. For more information related to the competitive landscape of multiplex PCR microarray analyzers, see “Industry Overview — Overview of Non-sequencing Molecular Testing Market — Overview of Multiplex PCR-Microarray Testing.”

Our AxiLona EL-100 was strategically developed to address substantial market opportunities. While not universally applicable to every end-user category, the platform demonstrates extensive market reach and customer base potential. Built on an innovative technology platform, the AxiLona EL-100 delivers cost-effective, high-multiplex detection capabilities that are particularly well-suited for pathogen detection and genetic disease screening applications. Notably, high-multiplex pathogen detection represents a significant market opportunity with diverse application scenarios.

Following receipt of the Class II medical device registration certificate for the AxiLona EL-100 microarray analyzer, we are actively developing various test kits by ourselves and pursuing collaborations with downstream partners across various sectors to co-develop specialized test kits, systematically expanding both clinical and research applications. Our commercialization strategy encompasses multiple pathways, including pursuing NMPA-approved in vitro diagnostic (IVD) kits, developing laboratory-developed tests (LDTs) tailored to specific clinical requirements, and offering RUO test kits. This flexible approach enables us to respond dynamically to end-user demands while capturing broader market opportunities.

AxiLona AXP-100, our Key Product

AxiLona AXP-100 EL-NGS gene sequencer, the world’s first EL-NGS platform, according to CIC, achieves an optimal balance across four critical metrics: accuracy (>99%), read length (single-molecule cyclic sequencing with repetitive consensus analysis based on simultaneous synthesis and sequencing), cost (significantly lower cost per Gigabases of data), and speed (up to one million reads concurrently). AxiLona AXP-100 can serve both clinical applications such as diagnoses of cancer and infectious disease and scientific research needs including structural variations study, and single-gene disease investigation. Research use refers to applications for scientific research purposes after the product has completed its design and development phase. Clinical applications refers to applications approved by national or local drug and food administration departments for clinical diagnosis.



Appearance of AxiLona AXP-100

SUMMARY

We launched the product prototype of AxiLona AXP-100 in 2021, and launched it for research use in 2023. We also plan to actively pursue the clinical application of AxiLona AXP-100. We completed the type testing for AxiLona AXP-100 in December 2025 in China and plan to initiate a clinical trial for AxiLona AXP-100 in the third quarter of 2026, after which we will pursue regulatory registration based on the trial outcomes.

As of December 31, 2025, 38 high-throughput gene sequencing instruments by 23 players had been approved by the NMPA or its local counterparts; while no EL-NGS instrument had received regulatory approval as of the same date. In 2024, the top five players in China’s high-throughput gene sequencing market collectively secured 95.8% of the market share by revenue, with the single largest player accounting for 47.0%. The EL-NGS segment, however, was still pre-commercial, with all instruments marketed for RUO. For more information related to the competitive landscape of high-throughput gene sequencing products, see “Industry Overview — Overview of Gene Sequencing Market — Competitive Landscape of High-Throughput Gene Sequencing Market.”

AxiLona AXP-1000

We plan to develop AxiLona AXP-1000, which would feature a higher throughput sequencing chip with ten million nanopore channels, offering nearly ten times the throughput of the AxiLona AXP-100. AxiLona AXP-1000 is currently in the design phase and we expect to complete the design of AxiLona AXP-1000 in the third quarter of 2026.

Test Kits

Our test kits comprise biochips, reagents and other necessary consumables. We are currently developing test kits for both of our molecular diagnostic products and EL-NGS platform. For example, we have been actively advancing development of specialized test kits for genetic disease detection and pathogenic microorganism detection. We completed design verification of the genetic disease detection test kits, and expect the pathogenic microorganism detection test kits targeting bacteria, viruses, and fungi to complete the design verification in the second quarter of 2026. Test kits are designed to be used in conjunction with AxiLona EL-100 and AxiLona AXP-100 for both clinical applications and RUO purposes. For details of different test kits, see “Business — Our Product and Service Portfolio — Test Kits.”

Other Product and Service Offerings

One of our key offerings extended based on our foundational technology is custom synthesis of chemical products, which involves tailored small molecule synthesis, optimization, and enhancement of biological activity. This service has been fully developed, and we have already delivered two batches of products to clients in 2024. Another fully developed service we offer is high-throughput protein mutagenesis services, which typically includes gene synthesis, mutant library construction, protein expression and purification, high-throughput screening of mutants, and sequence validation.

We are also developing service solutions for multi-omics protein detection. These potential offerings include our ELP solution for multiplex protein marker detection built on the EL-100 platform and our AXPP solution for protein sequencing based on our EL-NGS platform. The development of these solutions is part of our long-term strategy to extend our core platform capabilities.

In addition, we have previously participated in the development of a non-invasive saliva glucose monitor system designed for home-use point-of-care testing (POCT), using electrochemical detection technology. This saliva-based blood glucose monitoring solution enables users to obtain clinical-grade glucose readings through simple oral fluid collection, eliminating traditional blood sampling requirements. The development was conducted under a commissioned development arrangement with an industry research institution, and upon completion of the prototype development, all related rights and interests in the product were

SUMMARY

transferred to the commissioning party in accordance with the relevant agreements. This development experience and collaboration reflect our technical expertise and practical capabilities in electrochemical detection technologies and end-to-end product development.

The AxiLona Library Preparation Robotic System, a next-generation robotic platform for genomic workflow automation, represents our efforts to further expand product portfolio. The system combines industrial-grade robotic liquid handling, which achieves microliter-scale precision and enables the simultaneous processing of eight samples. Based on our internal testing, this system has demonstrated the potential to reduce processing time by approximately 50% compared to manual methods, while maintaining consistent library quality and yield. This robotic platform has already been integrated into our testing workflows, contributing to improved operational efficiency and consistency. Through a collaboration with a specialized liquid handling module manufacturer, we are incorporating high-quality robotic components and corresponding consumables into this system. We will enjoy the ownership of the patents related to such robotic system developed through the current partnership mode. In the future, we may forge additional partnerships with other industry players or suppliers to further enhance the automation and portability of sequencing workflows of our AxiLona Library Preparation Robotic System.

OUR TECHNOLOGY PLATFORMS

We focus on developing life science technology platforms, with core expertise spanning four key areas: integrated circuit chips, synthetic biology and chemical engineering, electrochemistry and microfluidics, and artificial intelligence.

Integrated Circuit Chip Technology

Our integrated circuit chip technology delivers meaningful improvements in gene sequencing and molecular diagnostics. Designed using complementary metal oxide semiconductor (CMOS) principles and a 300mm, 65-nm fabrication process, our Bio-CMOS chips achieve highest density with over one million parallel nanopore detection cells per chip (with completed design of next generation chip scaling to tens of millions), reducing sequencing costs significantly. Although our Bio-CMOS chip technology is primarily used in advanced DNA sequencing, it has also been instrumental in developing the high-performance microarray chips used for nucleic acid and protein-based medical testing applications of our AxiLona EL-100. The chip's precision is enhanced by alternating current (AC) impedance detection and lab-on-chip microfluidics, which minimizes noise and improves accuracy. Furthermore, its compatibility with standard semiconductor processes enables scaled mass production at reduced costs. This proprietary technology positions us as a key player in the integration of semiconductor innovation with life sciences applications.

Synthetic Biology and Chemical Engineering

Our synthetic biology and chemical engineering platform further facilitates our technological capabilities. Equipped with specialized synthesis and analytical tools, this platform supports high-purity, customized synthesis of DNA, RNA, phosphoramidites, oligonucleotides, and modified dNTP biomarkers. These specialized synthesis and modifications enhance the signal-to-noise ratio in our AxiLona EL-100's detection capabilities and AxiLona AXP-100's sequencing applications, improving data quality. Additionally, our AI-algorithm-assisted enzyme engineering capabilities, including microfluidics-based high-throughput protein screening (10^5 – 10^6 mutants) and rational design systems, have led to the discovery of salt-tolerant, high-performance polymerases that drive the performance of our diagnostic and sequencing products. This platform ensures we deliver solutions for the demanding molecular biology challenges.

SUMMARY

Electrochemical and Microfluidic Integration

Our Bio-CMOS chip’s integration of electrochemical biosensing and microfluidic precision delivers strong benefits for gene sequencing and molecular diagnostics. The AxiLona EL-100 translates these capabilities into clinical practice, with combining the electrochemical sensing with microfluidic sample handling capabilities. This technology enables ultra-low-cost instruments and test kits, high-density detection arrays with unparalleled sensitivity, accuracy, and speed. By eliminating bulky optical components, our approach enables miniaturized, portable and compact sequencing and diagnostic devices, making diagnostics more accessible. With its fast turnaround times and scalability, our electrochemical and microfluidic platform offers an innovative alternative for cost-effective and efficient molecular detection solutions, addressing a wide range of applications.

Our AI-Enabled Capabilities

Currently, the detection of AxiLona EL-100 process employs PCR polymerase, while the EL-NGS sequencing process makes use of polymerase. The performance of these enzymes is critical to the success of our products. AI plays an important part in our screening and engineering of enzymes, supporting improvements in precision and efficiency. Leveraging our expertise in synthetic biology and protein engineering, AI helps identify opportunities for the design and optimization of polymerases. Through AI-supported structural simulations and in-depth analyses, we can identify critical sites and refine enzyme modeling to achieve better performance. Additionally, AI enables the development of microfluidics-based high-throughput protein mutation systems. We have already established targeted gene mutation libraries using microfluidics-based PCR, facilitating protein-directed evolution through Compartmentalized Self-Replication. By integrating high-throughput screening results with algorithm-assisted rational design methodologies, our platform achieves high precision and efficiency in protein screening and modification. These advancements not only enhance the capabilities of our existing platforms but also expand our ability to provide comprehensive solutions in this domain.

Our AI-assisted multiplex panel design for AxiLona EL-100 integrates machine learning with multiple bioinformatics alignment algorithms to identify highly specific primer-probe binding sites, optimize physical and chemical parameters, and perform specificity validation. Leveraging existing PCR/qPCR datasets to train predictive models, the system estimates amplification efficiency, assesses dimerization risk, enables multi-objective optimization, and detects aberrant sequence that may compromise amplification performance.

OUR COMPETITIVE STRENGTHS

We believe the following competitive strengths have contributed to our success and differentiate us from our competitors.

- We are a frontrunner in integrated circuit biotechnology, specializing in the development of sophisticated life science tools, including molecular diagnostics products and electrochemical long-read next-generation sequencing (EL-NGS) platform, offering multi-omics solutions for life science research and clinical applications;
- We focus on developing foundational platforms, with core expertise spanning four key areas: integrated circuit chips, synthetic biology and chemical engineering, electrochemistry and microfluidics, and artificial intelligence. The integration of IC (integrated circuits), BT (biotechnology), and AI (artificial intelligence) creates a uniquely distinctive position for us in the industry;
- Robust and efficient R&D framework dedicated to fostering innovation and driving transformation;
- Integrated manufacturing and commercialization capabilities with a strategic and forward-looking outlook; and

SUMMARY

- A seasoned management team with interdisciplinary scientific expertise and deep industry insight.

See “Business — Competitive Strengths.”

OUR STRATEGIES

We intend to pursue the following strategies to further grow our business.

- Accelerate the development of our product portfolio to solidify our competitive edge in molecular diagnostic products and EL-NGS gene sequencing;
- Expand and strengthen our core technology platform to further solidify our unique integration of IC (integrated circuits), BT (biotechnology), and AI (artificial intelligence);
- Build up domestic and international commercialization capabilities to drive the successive commercialization of our product pipeline; and
- Further enhance manufacturing capacity for gene sequencing and molecular diagnostic products.

See “Business — Strategies.”

RISK FACTORS

We believe that there are certain risks involved in our operations, many of which are beyond our control. These risks are set out in “Risk Factors.” Some of the major risks we face include:

- Our future growth depends substantially on the success of our product candidates. If we are unable to successfully complete clinical development, obtain regulatory approval, commercialize our product candidates, or keep up with industry and technology developments, or if we experience significant delays in doing so, our business will be materially harmed;
- We may not be successful in developing, enhancing or adapting to new technologies and methodologies;
- We may not be able to develop new or improved products that are competitive or aligned with evolving gene technologies and customer needs in the market due to the intense market competition and the current dominance of certain key players, in a timely manner or at all;
- If clinical trials of our product candidates fail to demonstrate positive results to the satisfaction of regulatory authorities, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates;
- We have limited experience in marketing and sales of our products. There can be no assurance that we will be able to successfully commercialize our products, and as a result, our revenue and profitability could be materially and adversely affected;
- Our success depends on our ability to provide reliable, high-quality products and services and to rapidly evolve to meet our customers’ needs. If our products or services, or similar molecular diagnostics and gene sequencing services and products available in the market in general, do not meet the expectations of customers, our results of operations, reputation and business could suffer.

SUMMARY

RESEARCH AND DEVELOPMENT

As a life sciences company founded in the U.S. and grown in China, we have been actively pursuing a multi-national strategy. Over the years, we have strategically established four R&D centers across Silicon Valley, Shenzhen, Tianjin, and Wuxi, each equipped with sophisticated experimental facilities to fuel our R&D endeavors. As of the Latest Practicable Date, our sophisticated and stable R&D team comprised 68 members with multidisciplinary backgrounds and industry know-how across semiconductor, biotechnology and artificial intelligence, over 70% of whom hold doctorate or master’s degrees, including 11 core R&D personnel who are primarily responsible for key R&D functions such as instrumentation and electronics, chips, software and data, biochemistry, product application development and manufacturing process research. Globally, our founders have secured nearly a hundred issued patents, with several more under application. In 2024 and 2025, we incurred research and development expenses of US\$11.4 million and US\$8.9 million, respectively. For details, please refer to “Financial Information — Description of Selected Components of Consolidated Statements of Profit or Loss and Other Comprehensive Income — Research and Development Expenses.”

MANUFACTURING

We manufacture, assemble and test our products mainly at our 4,100 square-meter manufacturing center in Wuxi. We had three production lines, with an annual designed production capacity of 1,000 units of instruments and 100 thousand sets of test kits. Our manufacturing facility is designed to be in compliance with GMP requirements of China and applicable regulations in the EU. We are also accredited in accordance with the ISO 13485 quality standard. We have received the medical device production permit for AxiLona EL-100 from Jiangsu MPA in April 2025. As of the Latest Practicable Date, we had a manufacturing team of 19 employees. Leveraging our own production lines and in-house manufacturing personnel, we do not rely on any imported products or external CMOs (contract manufacturing organizations). We plan to build a new production line for our medical devices and test kits to expand our manufacturing capability to capture the growing market demand. For details, please refer to “Business — Manufacturing.”

SALES AND MARKETING

During the Track Record Period, we mainly sell our products directly to our customers and we expect direct sales to remain an important part of our distribution approach in the foreseeable future. To expand our commercial footprint both within our domestic market and overseas market in the future and penetrate the in-hospital market in anticipation of our products’ expanded clinical applications, we have started to engage distributors for the sales of our products. We formulate and implement a reasonable pricing strategy for our marketed products to stay competitive and profitable. We primarily sold our products with prices in a fixed range during the Track Record Period. We take into account a number of factors in determining price for our products, which primarily include our R&D, production and marketing costs and expenses, the perceived value of products and services, our market share, and the competitive landscape. For details, please refer to “Business — Sales and Marketing.”

OUR CUSTOMERS

During the Track Record Period, our customers were primarily research institutes and hospitals. In 2024 and 2025, the aggregate sales to our five largest customers accounted for 98.1% and 85.9% of our total revenue, respectively, and sales to our largest customer accounted for 24.8% and 53.9% of our total revenue, respectively. To the best knowledge of our Directors, none of our Directors, their respective associates or any of our Shareholders holding more than 5% of our issued share capital immediately following the completion of the [REDACTED] had an interest in any of our customers during the Track Record Period. For details, please refer to “Business — Our Customers.”

SUMMARY

OUR SUPPLIERS

During the Track Record Period, our suppliers mainly comprised of service providers across scientific research, facility operations, and professional technical support, and raw material suppliers. In 2024 and 2025, purchases from our five largest suppliers in aggregate accounted for 33.0% and 26.1% of our total purchases (including value added tax), respectively, and purchases from our largest supplier accounted for 10.8% and 7.0% of our total purchases for the same periods (including value added tax), respectively. To the best knowledge of our Directors, none of our Directors, their respective associates or any of our Shareholders holding more than 5% of our issued share capital immediately following the completion of the [REDACTED] had an interest in any of our suppliers during the Track Record Period. For details, please refer to “Business — Our Suppliers and Raw Materials.”

INTELLECTUAL PROPERTY RIGHTS

We have built an extensive intellectual property portfolio in China and overseas to protect our technologies, inventions and know-how. As of the Latest Practicable Date, we had 42 issued patents and 22 patent applications in China, 13 issued patents and 18 patent applications in the U.S. and other jurisdictions. We also have four layout-design of integrated circuits registered in China. Specifically, in relation to our Core Product, AxiLona EL-100, we had five issued patents and six patent applications as of the Latest Practicable Date. We believe there is no material legal impediment to obtain the approvals for these pending patents. As of the Latest Practicable Date, we had registered trademarks for our Company and our corporate logo in China and are seeking trademark protection for our Company and our corporate logo in the countries where available and appropriate. During the Track Record Period and up to the Latest Practicable Date, we were not involved in any material proceedings regarding intellectual property rights infringement claims against us or initiated by us. For details, please refer to “Business — Intellectual Property Rights.”

OUR SINGLE LARGEST SHAREHOLDER

Immediately following the completion of the [REDACTED] (assuming that the [REDACTED] is not exercised and without taking into account any Shares which may be allotted and issued under the Equity Incentive Plan), Dr. Tian will hold 55,233,000 Shares, representing approximately [REDACTED]% of the total issued share capital of our Company. Accordingly, Dr. Tian will be our single largest Shareholder after the [REDACTED]. See “Relationship with Our Single Largest Shareholder” for details.

OUR PRE-[REDACTED] INVESTORS

Since the establishment of our Group, we have received four rounds of Pre-[REDACTED] Investments from a number of Pre-[REDACTED] Investors. The aggregate proceeds from the Pre-[REDACTED] Investments amounted to approximately US\$115.7 million. The post-money valuation of our Group upon the completion of the Series B Financing was approximately US\$347.5 million. Our Pre-[REDACTED] Investors include certain Sophisticated Investors, namely AZ-CICC and YF Capital. For the principal terms of the Pre-[REDACTED] Investments and background information of the Pre-[REDACTED] Investors, see “History, Reorganization and Corporate Structure.”

EQUITY INCENTIVE PLAN

We adopted the Equity Incentive Plan. For details including a summary of the principal terms of the Equity Incentive Plan and the dilution impact resulting from full exercise of all outstanding share options granted thereunder, see “Appendix IV — Statutory and General Information — D. Equity Incentive Plan.”

SUMMARY

SUMMARY OF HISTORICAL FINANCIAL INFORMATION

The following tables set forth summary financial data from our consolidated financial information for the Track Record Period, extracted from the Accountants’ Report set out in Appendix I to this document. The summary consolidated financial data set forth below should be read together with, and is qualified in its entirety by reference to, the Accountants’ Report set out in Appendix I to this document, including the related notes. Our consolidated financial information was prepared in accordance with HKFRS Accounting Standards.

Summary of Consolidated Statements of Profit or Loss

The following table sets forth a summary of our consolidated statements of profit or loss and other comprehensive income for the years indicated.

	For the Year Ended December 31,	
	2024	2025
	(US\$ in thousands)	
Revenue	479	1,210
Cost of sales	(175)	(374)
Gross profit	304	836
Other income	2,063	1,007
Other gains and losses	(7,805)	(6,841)
Research and development expenses	(11,412)	(8,925)
Administrative expenses	(6,526)	(5,687)
Impairment losses recognised under expected credit loss model, net	–	(106)
[REDACTED]	[REDACTED]	[REDACTED]
Finance costs	(90)	(115)
Loss before tax	(23,466)	(22,272)
Income tax expense	–	–
Loss for the year	(23,466)	(22,272)
Other comprehensive (expense) income (item that may be reclassified subsequently to profit or loss)		
Exchange differences arising on translation of foreign operations	(187)	92
Total comprehensive expense for the year	(23,653)	(22,180)

Non-HKFRS Measure

To supplement our consolidated statements of profit or loss and other comprehensive income which are presented in accordance with HKFRS Accounting Standards, we also use adjusted loss as a non-HKFRS measure, which is not required by, or presented in accordance with, HKFRS Accounting Standards. We believe that the presentation of the non-HKFRS measure when shown in conjunction with the corresponding HKFRS measures provides useful information to management and **[REDACTED]** in facilitating a comparison of our operating performance from year to year.

SUMMARY

We define adjusted loss (non-HKFRS measure) as loss for the year/period adjusted by adding back (i) loss from changes in fair value of financial liabilities at FVTPL, (ii) [REDACTED] in relation to the proposed [REDACTED] and [REDACTED], and (iii) share-based payments. Loss from changes in fair value of financial liabilities at FVTPL represents the fair value changes of the Series A-1 Preferred Shares and Series B Preferred Shares held by our Pre-[REDACTED] Investors, which is non-cash in nature. Upon completion of the [REDACTED], the Series A-1 Preferred Shares and Series B Preferred Shares will be converted into ordinary shares of our Company. Share-based payments represent expenses arising from our grant of share options to eligible individuals, which are also non-cash in nature. The use of the non-HKFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for, or superior to, analysis of our results of operations or financial condition as reported under HKFRS Accounting Standards. In addition, the non-HKFRS financial measure may be defined differently from similar terms used by other companies and therefore may not be comparable to similar measures presented by other companies.

The following table reconciles our adjusted loss (non-HKFRS measure) for the year presented in accordance with HKFRS Accounting Standards, which is loss for the year:

	For the Year Ended December 31,	
	2024	2025
	<i>(US\$ in thousands)</i>	
Loss for the year	(23,466)	(22,272)
<i>Add:</i>		
Loss from changes in fair value of financial liabilities at FVTPL	7,610	6,850
[REDACTED]	[REDACTED]	[REDACTED]
Share-based payments	1,198	318
Adjusted loss (non-HKFRS measure) for the year	(14,658)	(12,663)

In 2024 and 2025, we recorded revenue of US\$479 thousand and US\$1,210 thousand, respectively, which was derived primarily from our sales of AxiLona AXP-100 for research use, and to a lesser extent, from provision of molecular diagnostics solutions to third-party customers. We had not generated revenue from commercial sales of our products and product candidates and were loss-making during the Track Record Period. Our net losses decreased slightly from US\$23.5 million in 2024 to US\$22.3 million in 2025, primarily due to a decrease of US\$2.5 million in research and development expenses, which is attributable to a decrease in staff costs driven by our reduced workforce and organizational streamlining, as well as a decrease in contract service fees following the conclusion of phased R&D initiatives for our Core Product AxiLona EL-100 in 2025; partially offset by an increase of US\$[REDACTED] in [REDACTED] in relation to the proposed [REDACTED] and [REDACTED]. Substantially all of our net losses resulted from research and development expenses and administrative expenses. For a detailed discussion of our net losses during the Track Record Period, see “Financial Information — Description of Selected Components of Consolidated Statements of Profit or Loss and Other Comprehensive Income.”

SUMMARY

Summary of Consolidated Statements of Financial Position

The following table sets forth summary data from our consolidated statements of financial position as of the dates indicated.

	As of December 31,	
	2024	2025
	<i>(US\$ in thousands)</i>	
Total non-current assets	5,480	3,966
Total current assets	39,707	28,786
Total current liabilities	102,745	112,649
Net current liabilities	(63,038)	(83,863)
Total assets less current liabilities	(57,558)	(79,897)
Total non-current liabilities	716	239
Net liabilities	58,274	(80,136)

Our net current liabilities increased from US\$63.0 million as of December 31, 2024 to US\$83.9 million as of December 31, 2025, primarily attributable to (i) a decrease of US\$12.4 million in bank balances and cash resulting from the cash outflows for our continued research and development activities and daily operations; and (ii) an increase of US\$6.9 million in financial liabilities at FVTPL in connection with the fair value changes of our Series A-1 Preferred Shares and Series B Preferred Shares.

Our net liabilities increased from US\$58.3 million as of December 31, 2024 to US\$80.1 million as of December 31, 2025, primarily attributable to our total comprehensive loss for the year of US\$22.2 million. For details, please refer to the Consolidated Statements of Changes in Equity as derived from the Accountants’ Report set out in Appendix I to this document.

All the Series A-1 Preferred Shares and Series B Preferred Shares that are classified as financial liabilities at FVTPL will be converted into ordinary shares of our Company and accounted as an increase in equity upon completion of the [REDACTED], such that our net liabilities position is expected to turn into a net assets position.

For details of our financial position, see “Financial Information — Discussion of Certain Selected Items from the Consolidated Statements of Financial Position.”

SUMMARY

Summary of Consolidated Statement of Cash Flows

The following table sets forth our selected cash flow data for the years indicated.

	For the Year Ended December 31,	
	2024	2025
	<i>(US\$ in thousands)</i>	
Operating cash flows before movements in working capital	(13,991)	(13,537)
Changes in working capital	(1,013)	(806)
Net cash used in operating activities	(15,004)	(14,318)
Net cash generated from investing activities	422	346
Net cash (used in) generated from financing activities	(2,607)	1,531
Net decrease in cash and cash equivalents	(17,189)	(12,441)
Cash and cash equivalents at beginning of the year	54,260	36,910
Effect of foreign exchange rate changes	(161)	85
Cash and cash equivalents at end of the year	36,910	24,554

In 2025, our cash used in operating activities was US\$14.3 million, which was primarily attributable to loss before tax of US\$22.3 million as adjusted by certain non-cash and working capital items. Positive adjustments primarily included (i) changes in fair value of financial liabilities at FVTPL of US\$6.9 million, and (ii) depreciation of property and equipment of US\$1,420 thousand. Negative adjustments primarily included (i) interest income of US\$793 thousand, and (ii) increase in inventories of US\$784 thousand.

In 2024, our net cash used in operating activities was US\$15.0 million, which was primarily attributable to loss before tax of US\$23.5 million as adjusted by certain non-cash and working capital items. Positive adjustments primarily included (i) change in fair value of financial liabilities at FVTPL of US\$7.6 million, (ii) depreciation of property and equipment of US\$1.4 million, and (iii) depreciation of right-of-use assets of US\$852 thousand. Negative adjustments primarily included (i) interest income of US\$1.5 million, and (ii) an increase of US\$1.0 million in trade and other receivables.

For more details of our cash flows, see “Financial Information — Liquidity and Capital Resources — Cash Flows.”

Our primary use of cash during the Track Record Period was to fund our research and development activities. We recorded net cash used in operating activities of US\$15.0 million and US\$14.3 million in 2024 and 2025, respectively. During the Track Record Period, we primarily funded our working capital requirements through equity and debt financings. Our management closely monitors use of cash and cash equivalents and strives to maintain a healthy liquidity for our operations. Going forward, we expect our liquidity requirements will be satisfied by a combination of existing cash and cash equivalents, bank loans, net [REDACTED] from the [REDACTED], as well as revenue derived from sales of our successfully commercialized products. With the continuing expansion of our business, we may require further funding through public or private offerings, debt financing, or other sources.

Our Directors are of the opinion that, taking into account the financial resources available to us, including bank balances and cash, unutilized bank facilities and the estimated

SUMMARY

net [REDACTED] from the [REDACTED], and considering our cash burn rate, we have available sufficient working capital to cover at least 125% of our costs, including research and development expenses, administrative expenses and other operating costs, for at least the next 12 months from the date of this document.

Our cash burn rate refers to the average monthly amount of net cash used in operating activities, capital expenditures and lease payments. We had bank balances and cash of US\$24.6 million as of December 31, 2025. We estimate that we will receive net [REDACTED] of approximately HK\$[REDACTED] million in the [REDACTED], assuming an [REDACTED] of HK\$[REDACTED] per Share, being the low end of the [REDACTED]. Assuming an average cash burn rate going forward of 1.5 times the level in 2025, we estimate that our bank balances and cash as of December 31, 2025 will be able to maintain our financial viability for [REDACTED] months, or, if we take into account the estimated net [REDACTED] from the [REDACTED], [REDACTED] months. We will continue to monitor our cash flows from operations closely and expect to raise our next round of financing no earlier than six months after the completion of the [REDACTED]. For more information related to our working capital sufficiency, see “Financial Information — Working Capital Confirmation.”

Key Financial Ratios

The following table sets forth our key financial ratios as of the dates indicated:

	As of December 31,	
	2024	2025
Current ratio ⁽¹⁾	0.4	0.3

Note:

- (1) Current ratio is calculated as current assets divided by current liabilities as of the end of the year/period.

For details, see “Financial Information — Key Financial Ratios.”

DIVIDENDS

We did not declare or pay any dividend during the Track Record Period. We did not have a formal dividend policy or pre-determined dividend payout ratio. We currently intend to retain all available funds and earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Our Board of Directors has complete discretion as to whether to distribute dividends, subject to certain restrictions under Cayman Islands law. Even if our Board of Directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our Board of Directors.

As advised by our legal advisor as to Cayman Islands laws, notwithstanding that the Company may have accumulated losses, the Company may declare dividend (a) out of profits of the Company if the Company has sufficient profits, unless such is contrary to the accounting principles adopted by the Company or (b) out of the share premium of the Company if following the date on which the dividend is proposed to be paid, the Company is able to pay its debts as they fall due in the ordinary course of business. In determining whether to declare a dividend, our Board will need to be satisfied that the declaration of dividend is in the best interest of the Company and may make provision for losses. [REDACTED] should not purchase our Shares with the expectation of receiving cash dividends.

RECENT DEVELOPMENTS

Since the end of the Track Record Period, we have been consistently advancing our product pipeline and developing our business, including actively progressing the

SUMMARY

commercialization of AxiLona EL-100. We expect that we will continue to record net losses for the year ending December 31, 2025, primarily because (i) we expect to incur significant research and development expenses as we continue to advance and expand our product pipeline and enhance our proprietary technology platforms; and (ii) we expect to incur [REDACTED] in connection with our proposed [REDACTED].

NO MATERIAL ADVERSE CHANGE

Our Directors confirm that, as of the date of this document, there has been no material adverse change in our financial and [REDACTED] positions or prospects since December 31, 2025, being the date on which our latest unaudited consolidated financial statements were prepared, and there has been no event since December 31, 2025 which would materially affect the information in the Accountants' Report set out in Appendix I to this document.

APPLICATION FOR [REDACTED] OF THE SHARES ON THE STOCK EXCHANGE

We have applied to the Stock Exchange for the [REDACTED] of, and permission to [REDACTED], the Shares in issue (including the Shares outstanding and to be converted from the Preferred Shares) and to be [REDACTED] pursuant to (i) the [REDACTED], (ii) the exercise of the [REDACTED], and (iii) the exercise of share options granted under the Equity Incentive Plan.

[REDACTED]

SUMMARY

[REDACTED]

SUMMARY

[REDACTED]

[REDACTED] to be borne by us are estimated to be approximately HK\$[REDACTED] million (including [REDACTED], assuming an [REDACTED] of HK\$[REDACTED] per Share, being the mid-point of the [REDACTED] of HK\$[REDACTED] to HK\$[REDACTED] per Share), which represent [REDACTED]% of the gross [REDACTED] from the [REDACTED], assuming no Shares are issued pursuant to the [REDACTED]. The above [REDACTED] are comprised of (i) [REDACTED]-related expenses of HK\$[REDACTED] million, and (ii) non-[REDACTED]-related expenses of HK\$[REDACTED] million, including (a) the legal advisors and the reporting accountants expenses of HK\$[REDACTED] million, and (b) other fees and expenses of HK\$[REDACTED] million. During the Track Record Period, we incurred [REDACTED] of HK\$[REDACTED] million, HK\$[REDACTED] million of which was charged to our consolidated statements of profit or loss, and HK\$[REDACTED] million of which was attributable to the issue of Shares and will be deducted from equity. We expect to incur additional [REDACTED] of approximately HK\$[REDACTED] million after the Track Record Period, of which approximately HK\$[REDACTED] million is expected to be charged to our consolidated statements of profit or loss, and approximately HK\$[REDACTED] million is attributable to the issue of Shares and will be deducted from equity upon [REDACTED]. The [REDACTED] above are the latest practicable estimate for reference only, and the actual amount may differ from this estimate.

USE OF [REDACTED]

We estimate that the aggregate net [REDACTED] to our Company from the [REDACTED] will be approximately HK\$[REDACTED] million, after deducting [REDACTED], fees and other estimated expenses in connection with the [REDACTED] paid and payable by us taking into account any additional discretionary incentive fee and assuming that the [REDACTED] is not exercised and an [REDACTED] of HK\$[REDACTED] per Share, being the mid-point of the [REDACTED] of HK\$[REDACTED] to HK\$[REDACTED] per Share.

We intend to apply such net [REDACTED] from the [REDACTED] for the following purposes:

- approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for further development, commercialization and manufacturing of AxiLona EL-100, our Core Product;
- approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for further development, commercialization and manufacturing of AxiLona AXP-100;
- approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for the development of AxiLona AXP-1000 and our other pipeline products;
- approximately [REDACTED]%, or HK\$[REDACTED] million, will be used to expand and strengthen our core technology platform to further solidify our unique integration of integrated circuits (IC), biotechnology (BT), and artificial intelligence (AI); and
- approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for working capital and general corporate purposes.

See “Future Plans and Use of [REDACTED]” for further details.